MedTrace Logo

Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble

NCT01215357 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-05-14

Study results available
· View outcomes & findings →

Summary

This study is designed to test the hypothesis that ecopipam is able to reduce urges to gamble in patients diagnosed with Pathological Gambling.

Conditions

  • Pathological Gambling

Interventions

DRUG

Ecopipam

50mg tablets

Sponsors & Collaborators

  • Psyadon Pharma

    collaborator INDUSTRY

  • Emalex Biosciences Inc.

    lead INDUSTRY

Principal Investigators

  • Jon Grant, MD · Univ. of Minnesota

  • Donald Black, MD · Iowa University

  • Timothy Fong, MD · University of California, Los Angeles

  • Marc Potenza, MD · Yale University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-05-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01215357 on ClinicalTrials.gov